Category Archives: Events

Join us for an insightful session on March 27th, featuring the first authors behind three influential 2025 papers on tertiary lymphoid structures (TLS) in cancer:

Masataka Amisaki, MD, PhD, MSKCC (USA)

Presenting a groundbreaking 2025 Nature paper, "IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer". Dr. Amisaki’s work deepens our understanding of TLS biology and paves the way for innovative therapeutic strategies for transforming “cold” tumors into immunologically active environments.

Florent Peyraud, MD, PhD, Institut Bergonié (France)

Sharing findings from his PhD research, conducted at Explicyte, Dr. Peyaud will discuss 2 publications:

• A research paper in Cell Reports Medicine titled "Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures"


• A comprehensive review in Med. titled "Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside"

Session Introduction

Immunologist Alban Bessede, PhD, CEO of Explicyte, will kick off the session. Dr Bessede has been working on TLS since 2020, co-authoring foundational papers in Nature Cancer and Nature Medicine on TLS & immune-checkpoint inhibitors, and is now developing accredited pathology services for detecting and scoring TLS in tumor specimens to support precision oncology initiatives.

 

Register for the webinar

Since 2021, Explicyte has developed a specific expertise in Tertiary Lymphoid Structure (TLS) detection and scoring by digital pathology. Hosted by Alban Bessede, PhD, CEO of Explicyte, this 45-minute webinar dedicated to TLS modulation in cancer immunotherapy will feature 2 presentations:

Tertiary lymphoid structures as modulators of anti-tumor immunity: what do we know and where are we headed?

Tullia C. Bruno, PhD - UPMC Hillman Cancer Center / University of Pittsburgh

Following a PhD thesis on intratumoral T cells at Johns Hopkins in 2010, Tullia Bruno started working on the role of B cells in the TME during her postdoctoral fellowship at the University of Colorado Denver. In 2015, she joined the University of Pittsburgh as an Assistant Professor to investigate the role of intratumoral B cell function within TLS in solid tumors. Focused on translational research and the development of novel immunotherapies, she is also a faculty member in the Tumor Microenvironment Center and the Cancer Immunology and Immunotherapy Program at the UPMC Hillman Cancer Center.

Predictive role of TLS for cancer immunotherapy: current insights and perspectives

Pr Antoine Italiano, MD, PhD - Institut Bergonié & Gustave Roussy Comprehensive Cancer Centers

Author of 500+ peer-reviewed publications, Pr. Italiano has been the Principal Investigator of 50+ clinical trials over the past 5 years, investigating the resistance mechanisms to cancer immunotherapies in solid tumors. Trained as a medical oncologist in France, he obtained a PhD in Molecular & Cell Biology in 2008. He then joined the laboratory of Cristina Antonescu for a post-doctoral fellowship at the MSKCC (New York, USA). He is currently leading Early Phase Trials and Sarcoma Units at Institut Bergonié (Bordeaux, France) and the head of the Precision Medicine unit at Gustave Roussy (Villejuif, France).

More about Explicyte's capacities for TLS detection & scoring in patient specimens

Register for the webinar